ONCOassist® | The go-to oncology app
@oncoassist.bsky.social
The go-to app for oncology professionals. Access all the clinical tools & information you need at point of care. CE approved.
oncoassist.com
oncoassist.com
📝Access mCRPC treatment guidance in seconds with ONCOassist
#mCRPC #ProstateCancer #OncologyTools #CancerCare #ClinicalOncology #DigitalHealth #OncologyApp #AdvancedProstateCancer #oncologytools
#mCRPC #ProstateCancer #OncologyTools #CancerCare #ClinicalOncology #DigitalHealth #OncologyApp #AdvancedProstateCancer #oncologytools
November 27, 2025 at 1:32 PM
📝Access mCRPC treatment guidance in seconds with ONCOassist
#mCRPC #ProstateCancer #OncologyTools #CancerCare #ClinicalOncology #DigitalHealth #OncologyApp #AdvancedProstateCancer #oncologytools
#mCRPC #ProstateCancer #OncologyTools #CancerCare #ClinicalOncology #DigitalHealth #OncologyApp #AdvancedProstateCancer #oncologytools
🚨Approval Alert!
✅ Imfinzi (durvalumab) becomes the first perioperative immunotherapy approved in the US for early gastric & GEJ cancers.
Phase III MATTERHORN data show strong outcomes:
🔹 29% lower risk of progression, recurrence or reduced OS.
🔹 22% lower risk of reduced OS vs. standard chemo
✅ Imfinzi (durvalumab) becomes the first perioperative immunotherapy approved in the US for early gastric & GEJ cancers.
Phase III MATTERHORN data show strong outcomes:
🔹 29% lower risk of progression, recurrence or reduced OS.
🔹 22% lower risk of reduced OS vs. standard chemo
November 26, 2025 at 10:30 AM
🚨Approval Alert!
✅ Imfinzi (durvalumab) becomes the first perioperative immunotherapy approved in the US for early gastric & GEJ cancers.
Phase III MATTERHORN data show strong outcomes:
🔹 29% lower risk of progression, recurrence or reduced OS.
🔹 22% lower risk of reduced OS vs. standard chemo
✅ Imfinzi (durvalumab) becomes the first perioperative immunotherapy approved in the US for early gastric & GEJ cancers.
Phase III MATTERHORN data show strong outcomes:
🔹 29% lower risk of progression, recurrence or reduced OS.
🔹 22% lower risk of reduced OS vs. standard chemo
🚨New in #Oncology!
🔔 PharmaEssentia, announces that positive results from its pivotal Phase 3 SURPASS-ET clinical trial have been published in The Lancet Haematology.
➡️ The SURPASS-ET compared ropeginterferon alfa-2b vs anagrelide in hydroxyurea-resistant/intolerant ET with leukocytosis.
🔔 PharmaEssentia, announces that positive results from its pivotal Phase 3 SURPASS-ET clinical trial have been published in The Lancet Haematology.
➡️ The SURPASS-ET compared ropeginterferon alfa-2b vs anagrelide in hydroxyurea-resistant/intolerant ET with leukocytosis.
November 25, 2025 at 12:30 PM
🚨New in #Oncology!
🔔 PharmaEssentia, announces that positive results from its pivotal Phase 3 SURPASS-ET clinical trial have been published in The Lancet Haematology.
➡️ The SURPASS-ET compared ropeginterferon alfa-2b vs anagrelide in hydroxyurea-resistant/intolerant ET with leukocytosis.
🔔 PharmaEssentia, announces that positive results from its pivotal Phase 3 SURPASS-ET clinical trial have been published in The Lancet Haematology.
➡️ The SURPASS-ET compared ropeginterferon alfa-2b vs anagrelide in hydroxyurea-resistant/intolerant ET with leukocytosis.
🚨Latest Approval Alert!
🔔 The EC approves expanded use of Breyanzi® (lisocabtagene maraleucel; liso-cel) for R/R Mantle Cell Lymphoma (MCL).
🧬 In the TRANSCEND MCL trial, 82.7% of patients responded, with 71.6% achieving a complete response, and over 50% maintaining response at 24 months.
🔔 The EC approves expanded use of Breyanzi® (lisocabtagene maraleucel; liso-cel) for R/R Mantle Cell Lymphoma (MCL).
🧬 In the TRANSCEND MCL trial, 82.7% of patients responded, with 71.6% achieving a complete response, and over 50% maintaining response at 24 months.
November 25, 2025 at 10:30 AM
🚨Latest Approval Alert!
🔔 The EC approves expanded use of Breyanzi® (lisocabtagene maraleucel; liso-cel) for R/R Mantle Cell Lymphoma (MCL).
🧬 In the TRANSCEND MCL trial, 82.7% of patients responded, with 71.6% achieving a complete response, and over 50% maintaining response at 24 months.
🔔 The EC approves expanded use of Breyanzi® (lisocabtagene maraleucel; liso-cel) for R/R Mantle Cell Lymphoma (MCL).
🧬 In the TRANSCEND MCL trial, 82.7% of patients responded, with 71.6% achieving a complete response, and over 50% maintaining response at 24 months.
🚨FDA Approval Update!
🔔 The FDA has approved pembrolizumab in combination with enfortumab vedotin-ejfv as a neoadjuvant + adjuvant treatment for adults with MIBC who are ineligible for cisplatin.
🎯 The major efficacy outcome measure was EFS assessed by blinded independent central review.
🔔 The FDA has approved pembrolizumab in combination with enfortumab vedotin-ejfv as a neoadjuvant + adjuvant treatment for adults with MIBC who are ineligible for cisplatin.
🎯 The major efficacy outcome measure was EFS assessed by blinded independent central review.
November 24, 2025 at 10:30 AM
🚨FDA Approval Update!
🔔 The FDA has approved pembrolizumab in combination with enfortumab vedotin-ejfv as a neoadjuvant + adjuvant treatment for adults with MIBC who are ineligible for cisplatin.
🎯 The major efficacy outcome measure was EFS assessed by blinded independent central review.
🔔 The FDA has approved pembrolizumab in combination with enfortumab vedotin-ejfv as a neoadjuvant + adjuvant treatment for adults with MIBC who are ineligible for cisplatin.
🎯 The major efficacy outcome measure was EFS assessed by blinded independent central review.
🚨FDA Approval Alert!
🔔 FDA grants accelerated approval to Sevabertinib for adults with metastatic non-squamous NSCLC harboring HER2 TKD activating mutations after prior systemic therapy.
➡️ FDA also clears the Oncomine Dx Target Test as a companion diagnostic to identify eligible patients.
🔔 FDA grants accelerated approval to Sevabertinib for adults with metastatic non-squamous NSCLC harboring HER2 TKD activating mutations after prior systemic therapy.
➡️ FDA also clears the Oncomine Dx Target Test as a companion diagnostic to identify eligible patients.
November 21, 2025 at 2:30 PM
🚨FDA Approval Alert!
🔔 FDA grants accelerated approval to Sevabertinib for adults with metastatic non-squamous NSCLC harboring HER2 TKD activating mutations after prior systemic therapy.
➡️ FDA also clears the Oncomine Dx Target Test as a companion diagnostic to identify eligible patients.
🔔 FDA grants accelerated approval to Sevabertinib for adults with metastatic non-squamous NSCLC harboring HER2 TKD activating mutations after prior systemic therapy.
➡️ FDA also clears the Oncomine Dx Target Test as a companion diagnostic to identify eligible patients.
🚨FDA Approval Alert!
🔔 The FDA has granted full approval to daratumumab and hyaluronidase-fihj plus VCd for newly diagnosed light chain (AL) amyloidosis, converting its 2021 accelerated approval to traditional approval.
✅ This decision is supported by results from the ANDROMEDA Phase 3 trial.
🔔 The FDA has granted full approval to daratumumab and hyaluronidase-fihj plus VCd for newly diagnosed light chain (AL) amyloidosis, converting its 2021 accelerated approval to traditional approval.
✅ This decision is supported by results from the ANDROMEDA Phase 3 trial.
November 21, 2025 at 12:30 PM
🚨FDA Approval Alert!
🔔 The FDA has granted full approval to daratumumab and hyaluronidase-fihj plus VCd for newly diagnosed light chain (AL) amyloidosis, converting its 2021 accelerated approval to traditional approval.
✅ This decision is supported by results from the ANDROMEDA Phase 3 trial.
🔔 The FDA has granted full approval to daratumumab and hyaluronidase-fihj plus VCd for newly diagnosed light chain (AL) amyloidosis, converting its 2021 accelerated approval to traditional approval.
✅ This decision is supported by results from the ANDROMEDA Phase 3 trial.
🚨FDA Approval Alert!
📢 FDA approves selumetinib(KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with NF1 experiencing symptomatic, inoperable plexiform neurofibromas.
🔹FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.
📢 FDA approves selumetinib(KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with NF1 experiencing symptomatic, inoperable plexiform neurofibromas.
🔹FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.
November 21, 2025 at 10:30 AM
🚨FDA Approval Alert!
📢 FDA approves selumetinib(KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with NF1 experiencing symptomatic, inoperable plexiform neurofibromas.
🔹FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.
📢 FDA approves selumetinib(KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with NF1 experiencing symptomatic, inoperable plexiform neurofibromas.
🔹FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.
🚨European Union Approval Alert!
✅ EU approves Libtayo® (cemiplimab) as the first immunotherapy for adjuvant treatment of CSCC at high risk of recurrence after surgery and radiation.
📉 Phase 3 C-POST trial: Significant improvement in disease-free survival with a 68% reduction in recurrence.
✅ EU approves Libtayo® (cemiplimab) as the first immunotherapy for adjuvant treatment of CSCC at high risk of recurrence after surgery and radiation.
📉 Phase 3 C-POST trial: Significant improvement in disease-free survival with a 68% reduction in recurrence.
November 21, 2025 at 8:30 AM
🚨European Union Approval Alert!
✅ EU approves Libtayo® (cemiplimab) as the first immunotherapy for adjuvant treatment of CSCC at high risk of recurrence after surgery and radiation.
📉 Phase 3 C-POST trial: Significant improvement in disease-free survival with a 68% reduction in recurrence.
✅ EU approves Libtayo® (cemiplimab) as the first immunotherapy for adjuvant treatment of CSCC at high risk of recurrence after surgery and radiation.
📉 Phase 3 C-POST trial: Significant improvement in disease-free survival with a 68% reduction in recurrence.
🚨FDA Approval Alert!
✅ FDA grants full approval to Amgen's IMDELLTRA® (tarlatamab-dlle) in extensive stage small cell lung cancer (ES-SCLC).
🎯 Phase 3 DeLLphi-304 shows 40% reduction in risk of death vs chemo.
🔗 Read more: bit.ly/ONCOnews20N3
#ONCOnews #OncoAlert #OncEd #Oncology #CancerUpdates
✅ FDA grants full approval to Amgen's IMDELLTRA® (tarlatamab-dlle) in extensive stage small cell lung cancer (ES-SCLC).
🎯 Phase 3 DeLLphi-304 shows 40% reduction in risk of death vs chemo.
🔗 Read more: bit.ly/ONCOnews20N3
#ONCOnews #OncoAlert #OncEd #Oncology #CancerUpdates
November 20, 2025 at 3:00 PM
🚨FDA Approval Alert!
✅ FDA grants full approval to Amgen's IMDELLTRA® (tarlatamab-dlle) in extensive stage small cell lung cancer (ES-SCLC).
🎯 Phase 3 DeLLphi-304 shows 40% reduction in risk of death vs chemo.
🔗 Read more: bit.ly/ONCOnews20N3
#ONCOnews #OncoAlert #OncEd #Oncology #CancerUpdates
✅ FDA grants full approval to Amgen's IMDELLTRA® (tarlatamab-dlle) in extensive stage small cell lung cancer (ES-SCLC).
🎯 Phase 3 DeLLphi-304 shows 40% reduction in risk of death vs chemo.
🔗 Read more: bit.ly/ONCOnews20N3
#ONCOnews #OncoAlert #OncEd #Oncology #CancerUpdates
📝Access CTCAE v6 toxicity grading in seconds in ONCOassist
The CTCAE criteria are designed to standardise adverse event reporting in oncology research and practice.
#ONCOassist #CTCAEv6 #ToxicityGrading #AdverseEvents #OncologyTools #DigitalHealth #CancerCare #ClinicalOncology #OncologyApp
The CTCAE criteria are designed to standardise adverse event reporting in oncology research and practice.
#ONCOassist #CTCAEv6 #ToxicityGrading #AdverseEvents #OncologyTools #DigitalHealth #CancerCare #ClinicalOncology #OncologyApp
November 20, 2025 at 1:08 PM
📝Access CTCAE v6 toxicity grading in seconds in ONCOassist
The CTCAE criteria are designed to standardise adverse event reporting in oncology research and practice.
#ONCOassist #CTCAEv6 #ToxicityGrading #AdverseEvents #OncologyTools #DigitalHealth #CancerCare #ClinicalOncology #OncologyApp
The CTCAE criteria are designed to standardise adverse event reporting in oncology research and practice.
#ONCOassist #CTCAEv6 #ToxicityGrading #AdverseEvents #OncologyTools #DigitalHealth #CancerCare #ClinicalOncology #OncologyApp
🚨Latest in Oncology!
🆕 EU approves Roche’s Lunsumio® (mosunetuzumab) subcutaneous (SC) for relapsed/refractory follicular lymphoma — offering durable responses even in later-line disease.
⏱️ New SC option cuts administration time to ~1 minute, supporting greater treatment flexibility for patients.
🆕 EU approves Roche’s Lunsumio® (mosunetuzumab) subcutaneous (SC) for relapsed/refractory follicular lymphoma — offering durable responses even in later-line disease.
⏱️ New SC option cuts administration time to ~1 minute, supporting greater treatment flexibility for patients.
November 20, 2025 at 1:00 PM
🚨Latest in Oncology!
🆕 EU approves Roche’s Lunsumio® (mosunetuzumab) subcutaneous (SC) for relapsed/refractory follicular lymphoma — offering durable responses even in later-line disease.
⏱️ New SC option cuts administration time to ~1 minute, supporting greater treatment flexibility for patients.
🆕 EU approves Roche’s Lunsumio® (mosunetuzumab) subcutaneous (SC) for relapsed/refractory follicular lymphoma — offering durable responses even in later-line disease.
⏱️ New SC option cuts administration time to ~1 minute, supporting greater treatment flexibility for patients.
🚨New EC Approval!
🔔 The European Commission has approved subcutaneous KEYTRUDA® (pembrolizumab) for all adult EU-approved indications — becoming the first and only subcutaneous immune checkpoint inhibitor in Europe.
🔗 Read more: bit.ly/ONCOnews20N-1
#ONCOnews #OncoAlert #OncEd #Oncology
🔔 The European Commission has approved subcutaneous KEYTRUDA® (pembrolizumab) for all adult EU-approved indications — becoming the first and only subcutaneous immune checkpoint inhibitor in Europe.
🔗 Read more: bit.ly/ONCOnews20N-1
#ONCOnews #OncoAlert #OncEd #Oncology
November 20, 2025 at 10:59 AM
🚨New EC Approval!
🔔 The European Commission has approved subcutaneous KEYTRUDA® (pembrolizumab) for all adult EU-approved indications — becoming the first and only subcutaneous immune checkpoint inhibitor in Europe.
🔗 Read more: bit.ly/ONCOnews20N-1
#ONCOnews #OncoAlert #OncEd #Oncology
🔔 The European Commission has approved subcutaneous KEYTRUDA® (pembrolizumab) for all adult EU-approved indications — becoming the first and only subcutaneous immune checkpoint inhibitor in Europe.
🔗 Read more: bit.ly/ONCOnews20N-1
#ONCOnews #OncoAlert #OncEd #Oncology
🚀 The CTCAE v6 now available in the #ONCOassist app!
🔹Stay up to date with the latest adverse event standards.
🔹Search and grade adverse events instantly.
🔹Streamline your documentation.
🔹Improve communication and safety in daily oncology practice.
➡️ CTCAE v4 & v5 are still available in the app.
🔹Stay up to date with the latest adverse event standards.
🔹Search and grade adverse events instantly.
🔹Streamline your documentation.
🔹Improve communication and safety in daily oncology practice.
➡️ CTCAE v4 & v5 are still available in the app.
November 19, 2025 at 1:30 PM
🚀 The CTCAE v6 now available in the #ONCOassist app!
🔹Stay up to date with the latest adverse event standards.
🔹Search and grade adverse events instantly.
🔹Streamline your documentation.
🔹Improve communication and safety in daily oncology practice.
➡️ CTCAE v4 & v5 are still available in the app.
🔹Stay up to date with the latest adverse event standards.
🔹Search and grade adverse events instantly.
🔹Streamline your documentation.
🔹Improve communication and safety in daily oncology practice.
➡️ CTCAE v4 & v5 are still available in the app.
🚨FDA Approval Alert!
✅ FDA approves EPKINLY® (epcoritamab-bysp) in combination with Rituximab and Lenalidomide for relapsed/refractory follicular lymphoma!
💥 First-ever bispecific antibody combination approved, delivering superior PFS & response rates in Phase 3 EPCORE FL-1 study.
✅ FDA approves EPKINLY® (epcoritamab-bysp) in combination with Rituximab and Lenalidomide for relapsed/refractory follicular lymphoma!
💥 First-ever bispecific antibody combination approved, delivering superior PFS & response rates in Phase 3 EPCORE FL-1 study.
November 19, 2025 at 12:30 PM
🚨FDA Approval Alert!
✅ FDA approves EPKINLY® (epcoritamab-bysp) in combination with Rituximab and Lenalidomide for relapsed/refractory follicular lymphoma!
💥 First-ever bispecific antibody combination approved, delivering superior PFS & response rates in Phase 3 EPCORE FL-1 study.
✅ FDA approves EPKINLY® (epcoritamab-bysp) in combination with Rituximab and Lenalidomide for relapsed/refractory follicular lymphoma!
💥 First-ever bispecific antibody combination approved, delivering superior PFS & response rates in Phase 3 EPCORE FL-1 study.
🚨Latest: Phase III results!
📣 Phase 3 results show ZIIHERA® (zanidatamab) delivers strong efficacy as a leading HER2-targeted therapy.
✅ Its combination with TEVIMBRA® (tislelizumab) + chemotherapy is emerging as a new first-line standard of care in HER2-positive gastroesophageal cancer.
📣 Phase 3 results show ZIIHERA® (zanidatamab) delivers strong efficacy as a leading HER2-targeted therapy.
✅ Its combination with TEVIMBRA® (tislelizumab) + chemotherapy is emerging as a new first-line standard of care in HER2-positive gastroesophageal cancer.
November 18, 2025 at 12:30 PM
🚨Latest: Phase III results!
📣 Phase 3 results show ZIIHERA® (zanidatamab) delivers strong efficacy as a leading HER2-targeted therapy.
✅ Its combination with TEVIMBRA® (tislelizumab) + chemotherapy is emerging as a new first-line standard of care in HER2-positive gastroesophageal cancer.
📣 Phase 3 results show ZIIHERA® (zanidatamab) delivers strong efficacy as a leading HER2-targeted therapy.
✅ Its combination with TEVIMBRA® (tislelizumab) + chemotherapy is emerging as a new first-line standard of care in HER2-positive gastroesophageal cancer.
🎗️Latest: Major advance in early breast cancer!
💊 Roche’s giredestrant becomes the first oral SERD to show superior iDFS vs standard endocrine therapy.
📈 A potential new standard of care emerges - lidERA trial delivers a second Phase III success after evERA trial.
🔗 Read more: bit.ly/ONCOnews18N-1
💊 Roche’s giredestrant becomes the first oral SERD to show superior iDFS vs standard endocrine therapy.
📈 A potential new standard of care emerges - lidERA trial delivers a second Phase III success after evERA trial.
🔗 Read more: bit.ly/ONCOnews18N-1
November 18, 2025 at 10:30 AM
🎗️Latest: Major advance in early breast cancer!
💊 Roche’s giredestrant becomes the first oral SERD to show superior iDFS vs standard endocrine therapy.
📈 A potential new standard of care emerges - lidERA trial delivers a second Phase III success after evERA trial.
🔗 Read more: bit.ly/ONCOnews18N-1
💊 Roche’s giredestrant becomes the first oral SERD to show superior iDFS vs standard endocrine therapy.
📈 A potential new standard of care emerges - lidERA trial delivers a second Phase III success after evERA trial.
🔗 Read more: bit.ly/ONCOnews18N-1
🚨FDA Approval Alert!
✅ FDA Approves First Ever Perjeta Biosimilar!
📢 Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) is now approved as an interchangeable biosimilar to Perjeta(pertuzumab, Genentech Inc.) for HER2+ breast cancer across metastatic, neoadjuvant, and adjuvant settings.
✅ FDA Approves First Ever Perjeta Biosimilar!
📢 Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) is now approved as an interchangeable biosimilar to Perjeta(pertuzumab, Genentech Inc.) for HER2+ breast cancer across metastatic, neoadjuvant, and adjuvant settings.
November 14, 2025 at 12:30 PM
🚨FDA Approval Alert!
✅ FDA Approves First Ever Perjeta Biosimilar!
📢 Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) is now approved as an interchangeable biosimilar to Perjeta(pertuzumab, Genentech Inc.) for HER2+ breast cancer across metastatic, neoadjuvant, and adjuvant settings.
✅ FDA Approves First Ever Perjeta Biosimilar!
📢 Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) is now approved as an interchangeable biosimilar to Perjeta(pertuzumab, Genentech Inc.) for HER2+ breast cancer across metastatic, neoadjuvant, and adjuvant settings.
🚨FDA Approval Alert!
✅ The FDA has approved ziftomenib (Komzifti), a menin inhibitor, for adults with relapsed/refractory AML harboring an NPM1 mutation who lack satisfactory treatment options.
🎯 Decision supported by the KO-MEN-001 trial evaluating efficacy and safety in 112 patients.
✅ The FDA has approved ziftomenib (Komzifti), a menin inhibitor, for adults with relapsed/refractory AML harboring an NPM1 mutation who lack satisfactory treatment options.
🎯 Decision supported by the KO-MEN-001 trial evaluating efficacy and safety in 112 patients.
November 14, 2025 at 10:30 AM
🚨FDA Approval Alert!
✅ The FDA has approved ziftomenib (Komzifti), a menin inhibitor, for adults with relapsed/refractory AML harboring an NPM1 mutation who lack satisfactory treatment options.
🎯 Decision supported by the KO-MEN-001 trial evaluating efficacy and safety in 112 patients.
✅ The FDA has approved ziftomenib (Komzifti), a menin inhibitor, for adults with relapsed/refractory AML harboring an NPM1 mutation who lack satisfactory treatment options.
🎯 Decision supported by the KO-MEN-001 trial evaluating efficacy and safety in 112 patients.
🧮 Calculate MASCC Risk Index in seconds with ONCOassist.
#ONCOassist #MASCC #FebrileNeutropenia #OncologyTools #DigitalHealth #SupportiveCare
#ONCOassist #MASCC #FebrileNeutropenia #OncologyTools #DigitalHealth #SupportiveCare
November 13, 2025 at 12:30 PM
🧮 Calculate MASCC Risk Index in seconds with ONCOassist.
#ONCOassist #MASCC #FebrileNeutropenia #OncologyTools #DigitalHealth #SupportiveCare
#ONCOassist #MASCC #FebrileNeutropenia #OncologyTools #DigitalHealth #SupportiveCare
🚨FDA Approval Alert!
✅ The FDA has approved Promega’s OncoMate® MSI Dx Analysis System as a companion diagnostic for KEYTRUDA® (pembrolizumab) + LENVIMA® (lenvatinib) in advanced endometrial carcinoma.
🔬 This MSI technology helps identify patients with microsatellite stable (MSS) disease.
✅ The FDA has approved Promega’s OncoMate® MSI Dx Analysis System as a companion diagnostic for KEYTRUDA® (pembrolizumab) + LENVIMA® (lenvatinib) in advanced endometrial carcinoma.
🔬 This MSI technology helps identify patients with microsatellite stable (MSS) disease.
November 12, 2025 at 12:30 PM
🚨FDA Approval Alert!
✅ The FDA has approved Promega’s OncoMate® MSI Dx Analysis System as a companion diagnostic for KEYTRUDA® (pembrolizumab) + LENVIMA® (lenvatinib) in advanced endometrial carcinoma.
🔬 This MSI technology helps identify patients with microsatellite stable (MSS) disease.
✅ The FDA has approved Promega’s OncoMate® MSI Dx Analysis System as a companion diagnostic for KEYTRUDA® (pembrolizumab) + LENVIMA® (lenvatinib) in advanced endometrial carcinoma.
🔬 This MSI technology helps identify patients with microsatellite stable (MSS) disease.
💥 How sharp is your oncology knowledge?
Meet ONCO-IQ — the new quiz-based feature inside #ONCOassist that turns learning into action.
Fast. Evidence-based.Interactive.
🎯 Take the quiz → buff.ly/kno5ObA
#Oncology #OncoAlert 🚨
@oncoalert.bsky.social
@myesmo.bsky.social
@ascopost.bsky.social
Meet ONCO-IQ — the new quiz-based feature inside #ONCOassist that turns learning into action.
Fast. Evidence-based.Interactive.
🎯 Take the quiz → buff.ly/kno5ObA
#Oncology #OncoAlert 🚨
@oncoalert.bsky.social
@myesmo.bsky.social
@ascopost.bsky.social
November 11, 2025 at 5:23 PM
💥 How sharp is your oncology knowledge?
Meet ONCO-IQ — the new quiz-based feature inside #ONCOassist that turns learning into action.
Fast. Evidence-based.Interactive.
🎯 Take the quiz → buff.ly/kno5ObA
#Oncology #OncoAlert 🚨
@oncoalert.bsky.social
@myesmo.bsky.social
@ascopost.bsky.social
Meet ONCO-IQ — the new quiz-based feature inside #ONCOassist that turns learning into action.
Fast. Evidence-based.Interactive.
🎯 Take the quiz → buff.ly/kno5ObA
#Oncology #OncoAlert 🚨
@oncoalert.bsky.social
@myesmo.bsky.social
@ascopost.bsky.social
🩺 Dr Jasmin Hundal shares the new Liver Segmental Anatomy Tool in
@ONCOassist
. A fast, visual guide for clinicians & surgeons.
Watch now: youtu.be/WwFUqUa6OJI
#LiverAnatomy #Couinaud #OncologyTools #ONCOassist #Radiology #CTscan #Oncoalert
@HundalJasmin
@ONCOassist
. A fast, visual guide for clinicians & surgeons.
Watch now: youtu.be/WwFUqUa6OJI
#LiverAnatomy #Couinaud #OncologyTools #ONCOassist #Radiology #CTscan #Oncoalert
@HundalJasmin
Oncology Tools - Dr Jasmin Hundal introduces the Liver Segmental Anatomy Tool in ONCOassist
🎥 Oncology Tools | Featuring Dr. Jasmin Hundal
Dr. Jasmin Hundal, Hematology/Oncology Fellow at Cleveland Clinic (Ohio, USA), introduces the new Liver Anatomy - Couinaud Segmental Classification…
youtu.be
November 11, 2025 at 1:26 PM
🩺 Dr Jasmin Hundal shares the new Liver Segmental Anatomy Tool in
@ONCOassist
. A fast, visual guide for clinicians & surgeons.
Watch now: youtu.be/WwFUqUa6OJI
#LiverAnatomy #Couinaud #OncologyTools #ONCOassist #Radiology #CTscan #Oncoalert
@HundalJasmin
@ONCOassist
. A fast, visual guide for clinicians & surgeons.
Watch now: youtu.be/WwFUqUa6OJI
#LiverAnatomy #Couinaud #OncologyTools #ONCOassist #Radiology #CTscan #Oncoalert
@HundalJasmin
🚨Breaking: Phase III Trial update!
📢 Reducing Daunorubicin (DNR) in induction therapy for children with favorable-prognosis B-lineage ALL shows promising results in Phase III AIEOP-BFM ALL 2009.
💊 Aim: Maintain high cure rates while minimizing anthracycline-related toxicity.
📢 Reducing Daunorubicin (DNR) in induction therapy for children with favorable-prognosis B-lineage ALL shows promising results in Phase III AIEOP-BFM ALL 2009.
💊 Aim: Maintain high cure rates while minimizing anthracycline-related toxicity.
November 11, 2025 at 12:30 PM
🚨Breaking: Phase III Trial update!
📢 Reducing Daunorubicin (DNR) in induction therapy for children with favorable-prognosis B-lineage ALL shows promising results in Phase III AIEOP-BFM ALL 2009.
💊 Aim: Maintain high cure rates while minimizing anthracycline-related toxicity.
📢 Reducing Daunorubicin (DNR) in induction therapy for children with favorable-prognosis B-lineage ALL shows promising results in Phase III AIEOP-BFM ALL 2009.
💊 Aim: Maintain high cure rates while minimizing anthracycline-related toxicity.
🚨New in #Oncology!
✅ Update from HARMONi-A Study Conducted by Akeso in China:
🔹 Ivonescimab + chemotherapy significantly improved overall survival (HR = 0.74) in 2L+ EGFRm NSCLC.
🔹 Marks the first Phase III trial of Ivonescimab to achieve a statistically significant OS benefit.
✅ Update from HARMONi-A Study Conducted by Akeso in China:
🔹 Ivonescimab + chemotherapy significantly improved overall survival (HR = 0.74) in 2L+ EGFRm NSCLC.
🔹 Marks the first Phase III trial of Ivonescimab to achieve a statistically significant OS benefit.
November 10, 2025 at 12:30 PM
🚨New in #Oncology!
✅ Update from HARMONi-A Study Conducted by Akeso in China:
🔹 Ivonescimab + chemotherapy significantly improved overall survival (HR = 0.74) in 2L+ EGFRm NSCLC.
🔹 Marks the first Phase III trial of Ivonescimab to achieve a statistically significant OS benefit.
✅ Update from HARMONi-A Study Conducted by Akeso in China:
🔹 Ivonescimab + chemotherapy significantly improved overall survival (HR = 0.74) in 2L+ EGFRm NSCLC.
🔹 Marks the first Phase III trial of Ivonescimab to achieve a statistically significant OS benefit.